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The urokinase-type plasminogen activator receptor (uPAR or
CD87) is a glycolipid-anchored membrane protein often expressed
in the microenvironment of invasive solid cancers and high levels
are generally associated with poor patient prognosis (Kriegbaum
et al., 2011 [1]). uPAR is organized as a dynamic modular protein
structure composed of three homologous Ly6/uPAR domains (LU).
This internally ﬂexible protein structure of uPAR enables an
allosteric regulation of the interactions with its two principal
ligands: the serine protease urokinase-type plasminogen activator
(uPA) and the provisional matrix protein vitronectin (Vn) (Mertens
et al., 2012; Gårdsvoll et al., 2011; Madsen et al., 2007 [2–4]). The
data presented here relates to the non-covalent trapping of one of
these biologically relevant uPAR-conformations by a novel class of
monoclonal antibodies (Zhao et al., 2015 [5]) and to the general
mapping of the topographic epitope landscape on uPAR. Thevier Inc. This is an open access article under the CC BY license
of Structural Chemistry, Fujian Institute of Research on the Structure of
an 350002, China.
igshospitalet, Copenhagen Biocenter, Ole Maaløes Vej 5, DK-2200 Copen-
ang), m-ploug@ﬁnsenlab.dk (M. Ploug).
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B. Zhao et al. / Data in Brief 5 (2015) 107–113108methods required to achieve these data include: (1) recombinant
expression and puriﬁcation of a uPAR-hybrid protein trapped in
the desired conformation [patent; WO 2013/020898 A12013];
(2) developing monoclonal antibodies with unique speciﬁcities
using this protein as antigen; (3) mapping the functional epitope
on uPAR for these mAbs by surface plasmon resonance with a
complete library of puriﬁed single-site uPAR mutants (Zhao et al.,
2015; Gårdsvoll et al., 2006 [5,6]); and ﬁnally (4) solving the three-
dimensional structures for one of these mAbs by X-ray crystal-
lography alone and in complex with uPAR [deposited in the PDB
database as 4QTH and 4QTI, respectively].
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Protein structure and biochemistry
ore speciﬁc sub-
ject areaTrapping a ﬂexible protein structure in a deﬁned conformation by mAbsype of data X-ray crystal structures, surface plasmon resonance studies (SPR), and gen-
eration of mAbs with deﬁned reactivityow data was
acquiredX-ray diffraction data were collected at Shanghai Synchrotron Radiation
Facility
SPR data was recorded on a CM5 chip with a Biacore3000™ (GE Healthcare
Life Sciences)ata format Processed
xperimental
factorsRecombinant proteins and monoclonal antibodies were afﬁnity puriﬁed to
high homogeneity before use.xperimental
featuresKinetic rate constants for the interaction between immobilized anti-uPAR
mAbs and recombinant uPAR mutants were determined by SPR, the structure
of the mAb uPAR complex was determined by X-ray crystallographyata source
locationNot applicableata accessibility The data is available from the related publication by Zhao et al. (http://www.
ncbi.nlm.nih.gov/pubmed/25659907), from the patent (WO 2013/020898
A12013) and the structures deposited in the Protein Data Bank (entries 4QTH
and 4QTI).Value of the data Deﬁnes the structure of a closed, active conformation of native uPARwt without covalent
modiﬁcations;
 deﬁnes a topographic epitope landscape on uPAR for 6 different bins of anti-uPAR mAbs;
 establish that occupancy of the Vn-binding site by mAbs drives uPAR into to its closed
conformation;
 data deﬁning this interdomain ﬂexibility are important for functional studies on uPAR biology;
 and for the future design of uPAR-targeted intervention studies in human disease [1,7-9].
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We have developed an experimental platform to map the functional and structural epitopes on
uPAR for anti-uPAR monoclonal antibodies by combining surface plasmon resonance studies (SPR)
with X-ray crystallography and the data is summarized in Fig. 1. We expressed the recombinant uPAR
variants in Drosophila S2-cells as soluble and secreted proteins by deleting the C-terminal signal
peptide required for membrane tethering by a glycosyl-phosphatidylinositol anchor [10]. The choice
of this particular host organism for recombinant uPAR expression is dual. First, the transfection
efﬁcacy of the S2 cells is extremely high rendering laborious sub-cloning superﬂuous in most cases.
Second, the simple and homogenous N-linked glycosylation patters provided by these cells are
advantageous for crystallization [11].
The initial mapping of the epitopes for new anti-PAR mAbs was performed by immobilizing the
antibody in question on a CM5 sensor chip™ (GE Helthcare) with conventional amide chemistry
(EDC/NHS). First, the kinetics rate constants (kon and koff) for the mAbuPAR interactions were
determined at low surface densities to minimize possible confounding effects from mass transport
limitations. Second, the domain reactivity of these mAbs was established by measuring the binding to
intact uPAR, uPAR DI, and uPAR DIIDIII. Third, epitope binning was performed by measuring whether
a second anti-uPAR mAb can bind to the uPAR captured by the immobilized mAb. Fourth, a complete
single-site epitope mapping was performed by measuring the kinetics between the immobilized mAb
and a library of puriﬁed single site uPAR mutants produced in S2 cells [3,6].
Those anti-uPAR mAbs with unique and relevant functional and/or structural properties were then
selected for further X-ray crystallography studies to provide a high-resolution structure of the
topography of the mAb uPAR binding interface and deﬁne which of the uPAR conformations is
selected by that particular mAb. The power of this approach is illustrated by the apparent convergent
evolution of the three-dimensional hot-spot conﬁguration of the binding interface between the
native biologic ligand (vitronectin) and the surrogate ligand (mAb 8B12) – see Fig. 5 in the original
publication [5]. This relationship is not evident from direct sequence alignments of the primary
structures of the mAbs in question and the natural ligand vitronectin. The summary of the topo-
graphic epitope landscape on human uPAR is illustrated below in Fig. 1 and this information provides
an important working tool for selecting those particular mAbs that are optimal for a given biological
experiment and the knowledge of the corresponding hot-spot residues on uPAR may in some caseFig. 1. Topographic landscape on human uPAR for different mAb epitope bins. The crystal structure of human uPAR is shown in
a surface representation (3BT1) with the individual LU domains color coded; DI (light gray), DII (dark gray) and DIII (wheat).
The receptor-binding domains of the natural ligands are shown as cartoon representation i.e. the serine protease urokinase
(GFD) and the matrix protein vitronectin (SMB). The deﬁned epitope bins are highlighted by colors: BIN 1 in red representing
mAbs R3, R21 and VIM-5; BIN 2 in cyan representing mAbs R5, R9, mR1 and R20; BIN 3 in blue representing mAb H2; BIN 4 in
green representing mAbs R4 and R8; BIN 5 in magenta representing mAbs R2, R24 and ATN-658; and BIN 6 in yellow
representing mAbs 8B12 and 19.10. The identities of the hot-spot residues in the individual bins are provided in Table 1 in the
original publication [5].
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of this “toolbox”, which is providing data on epitope-mapped anti-uPAR mAbs, is evident from the
following example. How do you choose the optimal reagent for functional blocking of uPAR-mediated
effects on cell adhesion? If mAbs from epitope bin 1 (i.e. R3 or R21) are selected as intervention agents
they will indeed abrogate uPAR-mediated adhesion on vitronectin in conditions with very low levels
of uPA [3,12,13], but this effect will critically depend on the level of uPAR-occupancy with uPA as
these mAbs will not bind uPAuPAR complexes [5]. Another confounding factor in such studies is the
observation that uPA-binding as such increases cell migration [4,14]. These complicating factors are,
nonetheless, minimized if anti-uPAR mAbs from bin 6 are selected as intervention agents, as mAbs
from this particular epitope bin (i.e. 8B12 or 19.10) inhibit vitronectin binding and uPAR-mediated cell
adhesion even under conditions when the receptor is completely saturated with uPA [5].2. Materials and methods
2.1. Recombinant protein production and design of a permanently closed uPAR variant
Drosophila S2 cells have proven to be an excellent host organism for heterologous expression of
recombinant human and mouse uPAR both with a view to biophysical structure determination by X-ray
crystallography [5,15–21], hydrogen–deuterium exchange [2,20,22] or small angle X-ray scattering [2] and
with a view to functional studies by surface plasmon resonance [6,18,23] and microtiter-based time-
resolved ﬂuorescence [24]. The recombinant uPAR protein is secreted from the transfected S2 cells to the
harvest ﬂuid due to the omission in the expression vector of a C-terminal signal sequence entailing the
post-translational addition of a glycosyl-phosphatidylinositol membrane anchor [10]. For a detailed
experimental protocol on uPAR expression in S2 cells please consult [11]. The secreted uPAR can be afﬁnity
puriﬁed with CNBr-activated Sepharose™ coupled to speciﬁc anti-uPAR mAbs (mAb R2 for human uPAR
and mAb KOR-1 for mouse uPAR) [6,25], the uPAR-binding endogenous ligand uPA or its receptor-binding
fragment ATF [26,27], or a small high-afﬁnity peptide antagonist developed by combinatorial chemistry
[25,28]. These protocols generally yields42mg puriﬁed uPAR per liter harvest ﬂuid. Relatively gentle
elution conditions can be applied in the case of afﬁnity puriﬁcationwith uPA-coupled Sepharose due to the
relatively high pKa of 5.8 for the uPA uPAR interaction [25,29].
If the protein in question is difﬁcult to express or the S2 cells do not thrive, very low expression yields
are obtained and this is often associated with co-puriﬁcation of a contaminating endogenous Drosophila-
protein (imaginal disk growth factor protein 2, GI:45476987). The downside of adding 0.5 mM Cu2þ ,
required for activation of the metallothionein promoter, is that it may promote precipitation of proteins
and/or lipids. From a practical point of view it is therefore important to add 20mM EDTA to the harvest
ﬂuid and thoroughly removed all microparticles by centrifugation or ﬁltration to improve the life-time of
the afﬁnity column by avoiding clotting. A second sensible precaution is to reverse ﬂow between sample
application and the washing and elution.
The successful application of S2 cell expression for recombinant uPAR production has furthermore
evolved into a new protocol for expression of other LU-domain containing proteins using the third
LU-domain in uPAR (DIII) as fusion partner and the anti-uPAR mAb R2 for detection, optimization of
expression yields, and puriﬁcation tag [30]. The DIII fusion tag can be placed N-terminally or
C-terminally dependent of the target protein in question [31,32]. If uPAR DIII is used as an N-terminal
tag it is advantageous to mutate Arg281 in the linker to a Gly to prevent unintentional cleavage at this
site during enterokinase-mediated excision of the target protein (unpublished).
Two different avenues have been explored to design a constitutively active uPAR that preferentially
populates the closed state, which is induced as a consequence of the high-afﬁnity binding of uPA [2,3]. The
ﬁrst approach was to introduce a disulﬁde bond between His47 and Asn259, which covalently tethers uPAR
DI and DIII [19,33]. The second approach was to make a GFD-uPAR-Fc chimera in which the N-terminal
receptor-binding growth factor-like domain of uPA (denoted GFD) is fused in-line via a linker to the
N-terminus of uPAR, which again is followed by a second linker and the Fc-region of IgG [patent; WO 2013/
020898 A12013]. This design entails a uni-molecular saturation mechanism permanently driving uPAR into
its closed conformation. The corresponding protein chimera was expressed by Chinese Hamster ovary
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was used for immunization giving rise to the mAbs denoted 13F6, 8B12, 10H6, 13D11, 10.10, AL6, AL38, and
BE18 [patent; WO 2013/020898 A12013].2.2. Real-time binding interaction by surface plasmon resonance
Tomap the functional epitope on uPAR for various anti-uPARmAbs to “single site resolution” the kinetic
rate constants (kon and koff) for themAbuPAR interaction in real-time by surface plasmon resonancewith a
Biacore 3000™was determined. To eliminate avidity effects andmass transport limitations, the mAbs were
covalently immobilized on a CM5™chip at a density of 5–6 pmol/mm2 by amine chemistry and
4250 uPAR mutants were subsequently tested as analytes in a multi-cycle format. Each uPAR mutant was
tested in a block comprising one buffer run, three runs of a 3-fold dilution of uPAR spanning 90 nM, 30, nM
and 10 nM, and one repeat analysis of 30 nM uPAR in the end of the block to demonstrate reproducibility.
The mAbs were regenerated between each cycle by two separate injections of 0.1 M acetic acid in 0.5 M
NaCl and 20 mM H3PO4. Generally these regeneration conditions were well-tolerated by the immobilized
mAbs allowing the run of 25–100 blocks to be completed before a new immobilization was required.
Quality checks consisted of running uPARwt every 15–20 block to detect any impairment in performance.
The running buffer was 10 mM Hepes (pH 7.4), 150 mM NaCl, 3 mM EDTA and 0.005% (v/v) P-20 and
binding interactions were conducted at 20 °C at a ﬂowrate of 50 ml/min.2.3. X-ray crystallography
Fab fragment of mAb 8B12 was generated by digestion with papain as described in the original
publication. The liberated Fab fragments was puriﬁed by Protein A column and anion exchange
chromatography using a MonoQ column. The Fab fragment was then mixed with recombinant human
uPAR in a molar ratio of 1:1.5. The complex was incubated at room temperature for half an hour, and
puriﬁed by size exclusion chromatography (Superdex 75 h 10/30, Pharmacia Biotech).
For crystallization, the Fab or the protein complex was dialyzed into a buffer of 10 mM Tris–HCl pH
7.4 without salt. All crystals were obtained by mixing the protein solution with an equal amount of
reservoir solution by the sitting-drop vapor-diffusion method at room temperature. Micro-seeding
was applied to improve the quality of the complex crystals. For data collection, the crystals of Fab
fragment and the complex were ﬂash-frozen in liquid nitrogen in the reservoir solution containing
10% DMSO and 20% Glycerol, respectively.
X-ray diffraction data was collected at the Shanghai Synchrotron Radiation Facility and were
processed using the HKL2000 suite. All crystal structures were solved by molecular replacement
using Molrep from the CCP4 program suite. The crystal structure of 8B12 Fab was solved using murine
125-2H Fab (2VXT) as the initial search model. The reﬁne 8B12 Fab fragment structure was used as
the initial search model for the structure determination of the protein complex. The position of uPAR
in the complex was found using the PDB entry 2FD6 by ﬁxing the position of 8B12 Fab. Both the 8B12
Fab and the complex were manual adjusted by COOT and reﬁned by REFMAC, were deposited in PDB
with the code 4QTH and 4QTI, respectively.Acknowledgment
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